IL6 and systemic sclerosis: For example, upregulation of TLR2 in SSc leads to an increase in secretion of pro-inflammatory cytokine IL-6 as a response to the endogenous ligand amyloid A, which is a marker of inflammation in patients with the disease[26–27].